Altre lingue Shionogi & Co., Ltd.

Azioni

4507

JP3347200002

Tempo differito Japan Exchange Altri mercati azionari 03:45:03 20/05/2024			Variaz. 5gg	Var. 1 gen.
7.250 ^JPY	+1,70%		-5,03%	+6,58%

14/05	Il Nikkei giapponese oscilla lateralmente in attesa di altri utili e dell'IPC statunitense	RE
13/05	La giapponese Shionogi afferma che il trattamento COVID non ha raggiunto l'endpoint nella fase avanzata della sperimentazione	RE

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Japan's Nikkei drifts sideways as more earnings, US CPI awaited	14/05
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease	13/05
MÄRKTE ASIEN/Börsen wenig verändert - Mazda sehr schwach	13/05
MÄRKTE ASIEN/Uneinheitlich - Anleger meiden Risiken vor US-Preisdaten	13/05
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	13/05
Shionogi - Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund	09/05
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30/04
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	25/04
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23/04
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19/04
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19/04
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	19/04
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	18/04
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12/04
Shionogi Completes Up to 75 Billion Yen Share Buyback	29/03
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	28/03
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	22/03
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	21/03
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08/03
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	07/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shionogi & Co., Ltd.

Azioni

4507

JP3347200002

Altre lingue

Filtri